Olmesartan/amlodipine: a review of its use in the management of hypertension

Figures & data

Figure 1 Mean change in seated systolic blood pressure (SeSBP) from baseline to weeks 2, 4, 6 and 8 with olmesartan (OLM) and amlodipine (AML) monotherapy and olmesartan/amlodipine combination therapy.

Notes: Based upon data presented by Chrysant et al.^46,47 For clarity, some dosages and combinations have been omitted from this Figure.

Table 1 The COACH trial – change in seated diastolic blood pressure (SeDBP) and seated systolic blood pressure (SeSBP) from baseline to week 8 in the intent-to-treat population (last observation carried forward)⁴⁶

Treatment group	No. of patients	Mean (SD) change in SeDBP, mmHg	Mean (SD) change in SeSBP, mmHg
Olmesartan
10 mg	160	−8.3 (9.28)**	−11.5 (15.23)**
20 mg	159	−9.2 (9.73)**	−13.8 (15.90)**
40 mg	160	−10.2 (10.69)**	−16.1 (16.58)**
Amlodipine
5 mg	161	−9.4 (8.25)**	−14.9 (14.95)**
10 mg	163	−12.7 (8.25)**	−19.7 (16.52)**
Olmesartan/amlodipine
20 mg/5 mg	160	−14.0 (9.07)**	−23.6 (14.86)**
40 mg/5 mg	157	−15.5 (8.15)**	−25.4 (14.70)**
40 mg/10 mg	161	−19.0 (8.90)**	−30.1 (15.91)**
Placebo	160	−3.1 (10.67)**	−4.8 (18.70)*

Notes:

* P < 0.05;

** P < 0.001.

Abbreviation: SD, standard deviation.

Table 2 The COACH trial – patients achieving the blood pressure target (<140/90 mmHg for patients with uncomplicated hypertension; <130/80 mmHg for patients with diabetes) after eight weeks of treatment (last observation carried forward)⁴⁶

Treatment group	No (%)
Olmesartan
10 mg (n = 160)	32 (20.0)
20 mg (n = 159)	42 (26.4)
40 mg (n = 160)	58 (36.3)
Amlodipine
5 mg (n = 161)	34 (21.1)
10 mg (n = 163)	53 (32.5)
Olmesartan/amlodipine
20 mg/5 mg (n = 160)	68 (42.5)*,†
40 mg/5 mg (n = 157)	80 (51.0)*,†
40 mg/10 mg (n = 161)	79 (49.1)*,†
Placebo (n = 160)	14 (8.8)

Notes:

* P < 0.005 vs olmesartan monotherapy at the same dosage;

† P < 0.001 vs amlodipine monotherapy at the same dosage.

Figure 2 Olmesartan/amlodipine combination therapy versus amlodipine monotherapy – mean change from baseline in seated blood pressure after eight weeks of randomized, double-blind treatment.⁴⁹

Notes: *p < 0.05; **p < 0.0001 vs AML 5 mg monotherapy.
Abbreviations: AML, amlodipine; OLM, olmesartan; SeBP, seated blood pressure; SeDBP, seated diastolic blood pressure; SeSBP, seated systolic blood pressure.

Figure 3 Olmesartan/amlodipine combination therapy versus amlodipine monotherapy – mean change from baseline in seated systolic blood pressure after eight weeks of randomized, double-blind, uptitrated treatment.⁴⁹

Notes: ^†Uptitration of non-responders: patients whose BP was not adequately controlled (SeDBP ≥90 mmHg and SeSBP ≥140 mmHg) during randomized treatment in Period II.
Abbreviations: AML, amlodipine; OLM, olmesartan; SeSBP, seated systolic blood pressure.

Figure 4 Mean levels of seated systolic blood pressure (SeSBP) at the start (week 0) and end of treatment (week 52) according to baseline SeSBP in all patients treated with olmesartan/amlodipine combination therapy in a randomized, double-blind study.⁵⁸

Note: Adapted with permission from Mourad and Le Joune. Effective systolic blood pressure reduction with olmesartan medoxomil/amlodipine combination therapy. Clin Drug Investig. 2009;29(6):419–425.

Figure 5 Proportion of patients who achieved the cumulative seated blood pressure (SeBP) goal of 140/90 mmHg in the BP-CRUSH study.⁵⁹

Abbreviations: AML, amlodipine; HCTZ, hydrochlorothiazide; OLM, olmesartan.

ChrysantSMelinoMKarkiSLeeJHeyrmanRThe combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety studyClin Ther200830458760418498909

 PubMed Web of Science ®Google Scholar

ChrysantSMelinoMKarkiSLeeJHeyrmanROnset of antihypertensive effect in patients with mild-to-severe hypertension treated with a combination of amlodipine besylate and olmesartan medoxomil compared with component monotherapy and placeboJ Clin Hypertens2008a26378 Suppl 1378

 Google Scholar

VolpeMBrommerPHaagUMieleCEfficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre studyClin Drug Investig20092911125

 PubMed Web of Science ®Google Scholar

MouradJJLe JeuneSEffective systolic blood pressure reduction with olmesartan medoxomil/amlodipine combination therapy: post hoc analysis of data from a randomized, double-blind, parallel-group, multicentre studyClin Drug Investig2009296419425

 PubMed Web of Science ®Google Scholar

WeirMHsuehWANesbittSDEffects on BP control of amlodipine (AML)/olmesartan medoxomil (OM), with or without hydrochlorothiazide (HCTZ), in patients not controlled by prior anti-hypertensive monotherapy2010: Presented as a late breaker at the American Society of Hypertension 25th Annual Scentific Meeting and Exposition2010New York

 Google Scholar